Protocol investigating the clinical utility of an objective measure of activity and attention (QbTest) on diagnostic and treatment decision-making in children and young people with ADHD-'Assessing QbTest utility in ADHD' (AQUA): A randomised controlled trial

BMJ Open

Volumn 4, Issue 12, 2015, Pages

  Hall, Charlotte L ^a   Walker, Gemma M ^a   Valentine, Althea Z ^a   Guo, Boliang ^a   Kaylor Hughes, Catherine ^a   James, Marilyn ^a   Daley, David ^b   Sayal, Kapil ^a   Hollis, Chris ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; ASSESSMENT OF HUMANS; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CHILDREN GLOBAL ASSESSMENT SCALE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSENSUS; CONSULTATION; CONTINUOUS PERFORMANCE TEST; COST; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPMENT AND WELLBEING ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEASIBILITY STUDY; HUMAN; IMPULSIVENESS; MULTICENTER STUDY (TOPIC); NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QB TEST; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SAMPLE SIZE; SNAP IV; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; FEMALE; HEALTH CARE QUALITY; MALE; MENTAL HEALTH; MOTOR ACTIVITY; MULTICENTER STUDY; PROCEDURES; PSYCHOMETRY; SINGLE BLIND PROCEDURE;

ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DECISION MAKING; DECISION MAKING, COMPUTER-ASSISTED; FEMALE; HUMANS; MALE; MENTAL HEALTH; MOTOR ACTIVITY; PSYCHOMETRICS; QUALITY ASSURANCE, HEALTH CARE; SINGLE-BLIND METHOD;

EID: 84920742486     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006838     Document Type: Article

References (44)

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults . Clinical Guideline 72. London: National Institute for Health and Clinical Excellence, 2008.
2. Magyary D, Brandt P. A decision tree and clinical paths for the assessment and management of children with ADHD. Issues Ment Health Nurs 2002;23.6:553-66.
3. Schlander M. Child and adolescent psychiatry and mental health. Child Adolesc Psychiatry Ment Health 2007;1:1-13.
4. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006;10:iii -iv, xiii-146.
5. D ' Amico F, Knapp M, Beecham J, et al. Use of services and associated costs for young adults with childhood hyperactivity/ conduct problems: 20-year follow-up. Br J Psychiatry 2014;204.6:441-7.
6. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:179-203.
7. Ogundele MO, Ayyash HF, Banerjee S. Role of computerised continuous performance task tests in ADHD. Prog Neurol Psychiatry 2011;15:8-13.
8. [No authors listed]. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD.Arch Gen Psychiatry1999;56:1073.
9. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment. Drug Saf 2009;32:1089-96.
10. Sonuga-Barke EJ, Sergeant JA, Nigg J, et al. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: nosologic and diagnostic implications. Child Adolesc Psychiatr Clin N Am 2008;17:367-84.
11. Forbes GB. Clinical utility of the test of variables of attention (TOVA) in the diagnosis of attention-deficit/hyperactivity disorder. J Clin Psychol 1998;54:461-76.
12. Sandford J, Turner A. Integrated visual and auditory continuous performance test manual. Richmond, VA: BrainTrain, 2002.
13. Riccio CA, Cohen MJ, Hynd GW, et al. Validity of the auditory continuous performance test in differentiating central processing auditory disorders with and without ADHD. J Learn Disabil 1996;29:561-66.
14. Conners CK, Staff MHS. Conners' continuous performance test II (CPT II V. 5) . North Tonawanda, NY: Multi-Health Systems Inc, 2000.
15. Vogt C, Williams T. Early identification of stimulant treatment responders, partial responders and non-responders using objective measures in children and adolescents with hyperkinetic disorder. Child Adolesc Ment Health 2011;16:144-9.
16. Losier BJ, McGrath PJ, Klein RM. Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry 1996;37:971-87.
17. Riccio CA, Waldrop JJ, Reynolds CR, et al. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 2001;13:326-35.
18. Fernandez-Jaen A, Fernandez-Mayoralas DM, Pardos A, et al. Clinical and cognitive response to extended-release methylphenidate (Medikinet) in attention deficit/hyperactivity disorder: efficacy evaluation. Adv Ther 2009;26:1097-110.
19. Huang YS, Chao CC, Wu YY, et al. Acute effects of methylphenidate on performance during the test of variables of attention in children with attention deficit/hyperactivity disorder. Psychiatry Clin Neurosci 2007;61:219-25.
20. Solanto M, Newcorn J, Vail L, et al . Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:663-71.
21. Ulberstad F. QbTest technical manual. Stockholm, Sweden: Qbtech AB, 2012.
22. Reh V, Schmidt M, Lam L, et al. Behavioral assessment of core ADHD symptoms using the QbTest. J Atten Disord 2013. Published Online 2013. doi:1087054712472981
23. Reh V, Schidt M, Rief W, et al. Preliminary evidence for altered motion tracking-based hyperactivity in ADHD siblings. Behav Brain Funct 2014;10:7.
24. Wehmeier PM, Schacht A, Wolff C, et al. Neuropsychological outcomes across the day in children with attention-deficit/ hyperactivity disorder treated with Atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. J Child Adolesc Psychopharmacol 2011;21:433-44.
25. Ramtvedt BE, Ronias E, Aabech HS, et al. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol 2013;23:597-604.
26. Günther T, Kahraman-Lanzerath B, Knospe EL, et al . Modulation of attention-deficit/hyperactivity disorder symptoms by short-and long-acting methylphenidate over the course of a day. J Child Adolesc Psychopharmacol 2012;22:131-8.
27. Vogt C, Shameli A. Assessments for attention-deficit hyperactivity disorder: use of objective measurements. The Psychiatrist 2011;35:380-83.
28. Oades RD, Myint A-M, Dauvermann MR, et al. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct 2010;6:32.
29. Goodman R, Ford T, Richards H, et al. The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. J Child Psychol Psychiatry 2000;41:645-5.
30. Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 1997;38:581-86.
31. Hill P, Taylor E. An auditable protocol for treating attention deficit/ hyperactivity disorder. Arch Dis Child 2001;84:404-09.
32. Swanson JM, Sandman CA, Deutsch C, et al. Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. Pediatrics 1983;72:49-55.
33. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31.
34. Wille N, Badia X, Bonsel G, et al . Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010;19:875-86.
35. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed. Measuring mental health needs. London: Gaskell, 2001:163-83.
36. Feiveson A. Power by simulation. Stata J 2002;2:107-24.
37. Van Belle G. Statistical rules of thumb. John Wiley & Sons, 2011.
38. Smeeth L, Ng ESW. Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Control Clin Trials 2002;23:409-21.
39. Elley CR, Kerse N, Chondros P, et al . Intraclass correlation coefficients from three cluster randomised controlled trials in primary and residential health care. Aust N Z J Public Health 2005;29:461-67.
40. Sayal K, Daley D, James M, et al. Protocol Evaluating the effectiveness of a school-based group programme for parents of children at risk of ADHD: the 'PArents, Teachers and CHildren WORKing Together (PATCHWORK)'cluster RCT protocol. BMJ Open 2012;2. pii: e001783.
41. Goldstein H. Multilevel statistical models. John Wiley & Sons, 2011.
42. Dinnes J, Deeks J, Kirby J, et al. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005;9:1-113, iii.
43. Mallett S, Halligan S, Thompson M, et al. Interpreting diagnostic accuracy studies for patient care. BMJ 2012;345:e3999.
44. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.